Search

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Giving Back to Those Who Serve Our Country

Volunteering to Strengthen the Human-Animal Bond

Helping a Local Community in a Time of Need

Our forward-looking approach drives breakthroughs

Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.

Life Forward

In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

Shelter Revamps Make for Strong Bonds, More Adoptions

MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US

MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.

Big Little Things: In cancer, small things make a big impact

Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

New consortium EUbOPEN will provide tools to unlock disease biolog

Boehringer Ingelheim wins 2023 Prix Galien USA

Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers